Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly

First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs. The aim is to identify clinic...

Descripción completa

Detalles Bibliográficos
Autores: Coopmans, Eva C., Korevaar, Tim I. M., van Meyel, Sebastiaan W.F., Daly, Adrian F., Chanson, Philippe, Brue,Thierry, Delemer, Brigitte, Hána, Václav, Colao, Annamaria, Carvalho, Davide, Jaffrain-Rea, Marie-lise, Stalla, Günter K., Fajardo Montañana, Carmen, Beckers, Albert, van der Lely, Aart J., Petrossians, Patrick, Neggers, Sebastian J. C. M. M.
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad Católica de Valencia San Vicente Mártir
Repositorio:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:inglés
OAI Identifier:oai:riucv.ucv.es:20.500.12466/7503
Acceso en línea:https://hdl.handle.net/20.500.12466/7503
Access Level:acceso abierto
Palabra clave:Acromegaly
First-generation somatostatin receptor ligands
Biochemical response
32 Ciencias Médicas
Descripción
Sumario:First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs. The aim is to identify clinical predictors of the biochemical response to fg-SRLs monotherapy defined as biochemical response (insulin-like growth factor (IGF)-1 ≤ 1.3 × ULN (upper limit of normal)), partial response (>20% relative IGF-1 reduction without normalization), and nonresponse (≤20% relative IGF-1 reduction), and IGF-1 reduction.

Similares en LA Referencia